ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search
  • 2022 American Transplant Congress

    Renal Function After Orthotopic Liver Transplantation

    N. Kemmer1, z. Alam2, S. Desai3, L. Grater4, K. Robichaux5, S. Mohammed5, M. Gosselin4, A. Kumar6, J. Buggs7

    1Transplant Hepatology, Tampa General Hospital, Tampa, FL, 2Lake Erie College of Osteopathic Medicine, Bradenton, FL, 3Western University of Osteopathic Medicine, Pomona, CA, 4University of Tampa, Tampa, FL, 5University of South Florida, Tampa, FL, 6Morsani College of Medicine, University of South Florida, Tampa, FL, 7Transplant Surgery, Tampa General Hospital, Tampa, FL

    *Purpose: Patients with end-stage liver disease are susceptible to renal dysfunction especially during liver transplantation (LTX). Continuous renal replacement therapy (CRRT) can be used to…
  • 2022 American Transplant Congress

    Pathological Changes in Kidney Allografts Associated with COVID-19 Vaccination

    S. Shelton, N. Hellenga, P. Burke

    Christiana Care Health System - Kidney Transplant Program, Newark, DE

    *Purpose: The Coronavirus Disease 2019 (COVID-19) pandemic prompted widespread vaccination for the immunosuppressed population starting in January 2021 with minimal information on safety outcomes. The…
  • 2022 American Transplant Congress

    Older Living Donor Kidneys Are Associated with Worse Recipient and Graft Survival Compared to Younger Donors

    A. P. Bregman1, R. Spong1, R. El-Rifai1, K. Swanson1, S. Jackson2, S. Riad1

    1Medicine, University of Minnesota, Minneapolis, MN, 2Analytics, Mhealth-Fairview, Minneapolis, MN

    *Purpose: Older living donors (LDs) are accepted more frequently to expand the donor pool. We sought to evaluate recipient outcomes from older LDs >70y.*Methods: Utilizing…
  • 2022 American Transplant Congress

    Nivolumab After Sorafenib Failure in Liver Recipients with HCC Recurrence

    J. Kwon

    Surgery, Samsung Medical Center, Seoul, Korea, Republic of

    *Purpose: Several treatments have recently been known for hepatocellcular carcinoma (HCC) who have failed to treat sorafenib. Immune checkpoint inhibitors have proven to be effective,…
  • 2022 American Transplant Congress

    Antibody-Mediated Kidney Allograft Rejection (ABMR) Monitoring and Intervention Based on ABMR Subtypes – A Step Towards Precision Diagnosis and Management

    A. Rizvi1, S. Hussain2, M. Kueht3, J. Fair3, A. Gamilla-Crudo4, M. Mujtaba4

    1Internal Medicine, Nephrology, University of Texas Medical Branch, Galveston, TX, 2University of Texas Medical Branch, Houston, TX, 3Surgery, University of Texas Medical Branch, Galveston, TX, 4University of Texas Medical Branch, Galveston, TX

    *Purpose: The monitoring of kidney allograft for early detection of antibody mediated rejection (ABMR) and subsequent intervention using traditional clinical parameters has been insufficient due…
  • 2022 American Transplant Congress

    Outcomes in Kidney Transplant Recipients 70 Years and Older

    J. Mehta, N. F. Okonkwo, A. Paramesh, K. Atiemo, M. Killackey, H. Jeon, A. Vijay

    Tulane University School of Medicine, New Orleans, LA

    *Purpose: Patients older than 70 years are the fastest-growing age group of patients requiring renal replacement therapy. This has resulted in a corresponding increase in…
  • 2022 American Transplant Congress

    Everolimus in Liver Transplantation for Diffuse, Unresectable Neuroendocrine Tumor

    J. M. Vanatta1, R. A. Helmick2, C. Eymard2, N. Nezakatgoo2, P. Horton2, J. P. Kothadia2, S. P. Nair2, J. D. Eason2

    1Transplantation, University of Tennessee/Methodist University Hospital, Memphis, TN, 2Transplantation, University of Tennessee, Memphis, TN

    *Purpose: Liver transplantation (LT) has emerged as a therapy in selected patients for neuroendocrine tumor (NET) by providing cytoreduction. Progression-free survival in NET has been…
  • 2022 American Transplant Congress

    The Role of Geography in Adult Heart Allocation Over the Last 5 Years

    K. Bradbrook1, R. Goff1, R. Daly2, S. Hall3

    1Research, United Network for Organ Sharing, Richmond, VA, 2Mayo Clinic, Rochester, MN, 3Baylor University Medical Center, Dallas, TX

    *Purpose: In the last 5 years two policies have impacted the role of geography in adult heart allocation including the 2018 adult heart policy which…
  • 2022 American Transplant Congress

    An Analysis of Serological Response and Infection Outcomes Following Oxford Astra-Zeneca (azd1222) and Pfizer-Biontech (mRNA BNT162b2) SARS-CoV-2 Vaccines in Kidney and Pancreas Transplant Patients

    A. Asderakis1, U. Khalid1, G. Koimtzis1, M. Ponsford2, L. Szabó1, L. Grant2, S. Jolles2, I. Humphreys3

    1Cardiff Transplant Unit, University Hospital of Wales, Cardiff, United Kingdom, 2Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom, 3Division of Infection and Immunity, Cardiff University, Cardiff, United Kingdom

    *Purpose: SARS-CoV-2 is associated with high mortality among transplant recipients. This study aims to compare the humoral responses between the Oxford-Astra-Zeneca(AZ) and BNT162b2(Pfizer-BioNTech) vaccines in…
  • 2022 American Transplant Congress

    Phenytoin To Expedite Sirolimus & Tacrolimus Elimination: A Case Report

    A. Lemke, B. A. Boilson, R. Razonable, S. A. Bernard

    Mayo Clinic, Rochester, MN

    *Purpose: Sirolimus (SIR), a mammalian target of rapamycin inhibitor (mTORi), may be used with or without a calcineurin inhibitor after heart transplant (HT). The anti-proliferative…
  • « Previous Page
  • 1
  • …
  • 135
  • 136
  • 137
  • 138
  • 139
  • …
  • 1683
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2026 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences